A host of celebrities including Lord Julian Fellowes, Matt Barber, Masterchef’s John Torode and TV presenter Lisa Faulkner helped raise £620,000 at the second Sugarplum Dinner raising funds for JDRF. Other well known guests who were in attendance included Downton Abbey creator Lord Julian Fellowes, actors Tom Ward and Matt Barber, the Rt Hon Theresa May MP and Arun Nayar.
They were entertained by performers from Gifford’s Circus and DJ Sam Young provided the music. There was also a live auction, which racehorse trainer Charlie Brooks
Ms May, who has diabetes herself, said: “I know from personal experience of the challenges that come with a diagnosis of type 1 diabetes. But these challenges are all the greater when type 1 diabetes affects a young child.
“Parents need the right kind of advice and support to help them navigate through the difficulties and ensure that their child can thrive. That’s why the work of Sugarplum Children is so important – supporting children and families and fundraising for JDRF’s efforts to treat, prevent and ultimately cure type 1 diabetes.”
Lord Julian Fellowes said: “It is a pleasure to support Jubie Wigan and the wonderful work she is doing with Sugarplum Children. Seeing her young daughter Aliena cope so gallantly with this cruel disease makes my resolve even stronger to do whatever I can to help and of course so many people feel the same.”
Last year Lord Fellowes donated the naming of a character in Downton Abbey, who turned out to be Rose’s future husband Atticus Aldridge. This year he offered a signed leather bound copy of the very first script of Downton Abbey, which went for a staggering £34,000.
Other prizes available at the auction included the opportunity to ride the Goodwood racecourse in front of the crowds alongside Gold Cup winning amateur jockey, Sam Waley-Cohen and a day behind-the-scenes with photographer Mario Testino. A dinner party cooked by John Torode went for £40,000, and as there was such a fight between the two highest bidders, John very generously agreed to offer a second dinner, raising an impressive £80,000 in total.
Matt Barber said: “I was truly honoured to be asked to participate in this fabulous evening especially since my character in Downton Abbey, Atticus Aldridge was born at the last Sugarplum Dinner! Hearing Jubie speak about life for her young daughter Aliena, who suffers with type 1 diabetes, is humbling, and I’m delighted to be able to support the charity in finding a cure for this awful disease.”
Jubie said: “To see so many friends and family together supporting children like my own daughter Aliena with type 1 diabetes is just so overwhelming.
“Their support will enable JDRF to continue to try and find a cure for this relentless disease. My target tonight is half a million pounds. I also hope tonight will help to remind people about the seriousness of this disease. With Sugarplum Children I set out to be the voice for those who are too little to shout about it themselves, and this dinner has most certainly provided a platform from which to do this.”
JDRF funds research to cure, treat and prevent type 1. The organisation works with the government, academia and industry to accelerate research in the UK and within healthcare policy to ensure that the outcomes of research are delivered to people with type 1 in the UK.
Karen Addington, chief executive of JDRF in the UK and the nation’s charity leader of the year 2015, said: “The Sugarplum Dinner was an utter triumph. A phenomenal amount has been raised by the event to support JDRF’s work to cure, treat and prevent type 1 diabetes.
“Furthermore, the presence of A-list celebrities backing the cause means awareness of type 1 diabetes is reaching new heights.
“JDRF is deeply thankful for all who were involved with the evening – especially Sugarplum Children founder Jubie Wigan and her incredible family”.
The Sugarplum Candle – On-Sale from 1st October
We are hugely excited to announce the launch of The Sugarplum Candle, in collaboration with Wick & Tallow, whose candles were born out of a love for good design, great fragrances and a deep respect for heritage and character. The partnership was given the go ahead by my daughter, Aliena, herself when she saw that Wick & Tallow’s logo is a unicorn, her favourite animal in the entire world (fantasy or otherwise). Once we saw Wick & Tallow’s logo we just knew this was the company that was meant to make the Sugarplum Candle – if Aliena believes in unicorns then we should all believe there can be a cure for this unrelenting condition.
And we hope you will be as excited by the partnership as we all are! The scent, which includes sweet and gentle notes of white fig and vanilla, not only will evoke thoughts of deliciously sumptuous sugarplums, but it will bring the light of hope, something those of us affected by type 1 cannot live without.
The Sugarplum Candle will be available from 1st October at www.wickandtallow.com, as well as at the Nina Campbell shop on Walton Street, and Soho Home, the lifestyle shop at the recently opened Soho Farmhouse in Greta Tew. The candle is £40 and for every one sold, £10 will go directly to JDRF.
Apologies for not having posted for a while – the past few months have been so busy, trying to juggle other work, and begin a mother, whilst organising the next Sugarplum Dinner in November, but I promise to write more regularly after the Summer. Just bear with me!
Aliena just celebrated her three year diaversary, on 20th July and as sad it makes me to realise to what degree type 1 has become such an intrinsic part of or lives, I also felt strangely uplifted, to look back at those first few months after diagnosis, and to see how far we have come in the way in which we manage it.
Happy holidays everyone!
The jab is hoped to be available within the next 10 years
Wednesday 11 March 2015
Scientists working to find a vaccine for type 1 diabetes have said it could be developed “within a generation”.
Researchers at several UK universities are to carry out tests and trials of prototype jabs as part of a £4.4 million project announced today.
They estimate the first working vaccines to help delay or possibly prevent type 1 diabetes, which affects about 300,000 people in the UK, could be available in the next 10 years.
People with type 1 diabetes, the most common found in children, are unable to produce the hormone insulin and require daily injections, a healthy diet and regular exercise.
The research, funded by Diabetes UK, Tesco and JDRF, is being announced at Diabetes UK’s annual Professional Conference at London’s ExCeL centre and will consist of four studies carried out at UK institutions.
King’s College London will lead the country’s first-ever trial of a prototype vaccine in children and teenagers living with the condition.
Cardiff University will aim to develop “immuno-therapy” trials in UK hospitals, training doctors and researchers, while Imperial College will look to recruit sufferers to take part and King’s College will establish laboratories to study the results.
A medical assistant administers an insulin shot to a diabetes patientDr Rankin added: “Today, type 1 diabetes is an unavoidable condition with a huge impact on the lives of more than 300,000 people in the UK. Managing diabetes is a daily struggle and too many people develop devastating health complications or die before their time.
“These studies will take us a long way towards changing that – bringing us closer than ever to preventing and ultimately curing the condition.
“None of this will be easy or happen overnight. The first vaccines will probably help people to delay the onset of type 1 diabetes rather than preventing it entirely.
“But even this would help to reduce the risk of serious complications, such as stroke, blindness and heart attacks. In the longer term, a fully effective vaccine would represent a huge medical breakthrough and could transform the lives of people with type 1 diabetes.”
Professor Colin Dayan, of Cardiff University, said: “Within four years we expect to see results from studies of more than six potential treatments, and within 10 years we hope to see the first vaccine therapies delivered to patients in the clinic.”
I was so excited to watch the arrival of ATTICUS ALDRIDGE to Downton Abbey last night – a character born at The Sugarplum Dinner last year, after I approached the hugely talented Julian Fellowes to ask if he might consider auctioning the chance to have a character in your name on the show…..he said yes, and Atticus is the result! My extremely generous friends bid a great deal of money to make this happen, choosing the name of their son, and what a perfectly Donwtonian name it is. Played by the very handsome Matt Barber, we hope he will be on our screens for a while.
All money raised at the dinner – the auction alone raised £156k – went to JDRF, the world’s largest research charity for Type 1 diabetes, and other projects by Sugarplum Children, so we are all hugely grateful to everyone who donated money during the dinner.
Downton has always been one of my favourite shows on television, but is now extra special, knowing that I helped make telly history and have been part of something very special. Now i have to hope we can offer the same auction prize next year…….watch this space!!
Long live Atticus!!!
Diabetes: a cure at last
Friday 10th October 2014The Times
© Times Newspapers Limited 2014
Scientist devoted 23 years to research after infant son developed condition Diabetes treatment is a ‘game-changer’
A cure for diabetes is within reach after scientists developed a treatment that eliminates the need for sufferers to inject insulin.
The therapy involves a one-off transplant of laboratory-grown pancreatic cells, which scientists have finally succeeded in producing in large enough volumes to be able to treat patients. The cells worked normally for many months when implanted into mice, and the first human patients should undergo the treatment in the next few years.
The breakthrough by Harvard scientists was hailed yesterday as a medical advance potentially as significant as the advent of antibiotics. Jose Oberholtzer, an expert in transplantation at the University of Illinois at Chicago, predicted the development would “leave a dent in the history of diabetes“.
About 400,000 people in Britain have type 1 diabetes, including 30,000 children. The breakthrough could also help 10 per cent of Britain’s three million type 2 diabetes sufferers.
The advance is the culmination of 23 years of research by the Harvard scientist Doug Melton, who began working on type 1 diabetes when his son, Sam, had the condition diagnosed in childhood.
Professor Melton said yesterday that his team was now just one step away from the finish line, adding: “It was gratifying to know that we could do something that we always thought was possible, but many people felt it wouldn’t work.
“If we had shown this was not possible, then I would have had to give up on this whole approach. Now I’m really energised.”
Chris Mason, professor of regenerative medicine at University College London, said that if confirmed in a clinical trial the impact on diabetes would be “a medical game-changer on a par with antibiotics and bacterial infections”. The scientists are now in the last stages of animal testing in nonhuman primates.
Type 1 diabetes, which normally begins in childhood, is an autoimmune disease in which the body kills off all its pancreatic beta cells. The cells produce insulin, which regulates blood sugar. Without beta cells, the body’s sugar levels fluctuate wildly, meaning that patients need to monitor glucose and typically inject insulin several times each day.
In a study, published today in the journal Cell, Professor Melton’s team used embryonic stem cells and adult cells that had been genetically “rewound”.
Both these cell types have the ability to turn into any cell type in the body, but require the right biochemical environment to be “coaxed” down a particular developmental route. Scientists have struggled for years to get the set-up right to produce the volumes of pancreatic cells that would be necessary for clinical use.
Professor Melton’s team appears to have cracked this problem by identifying an efficient way to turn both stem cell types into beta cells.
When the cells were tested in the laboratory, they produced insulin, responded to glucose and appeared to work normally for many months when implanted in mice.
Crucially, a single production line of cells could be used to treat all patients, rather than each person needing their own genetically matched treatment, the study suggests.
Before being transplanted into the mice, the cells were placed in a porous capsule, which allowed insulin to diffuse out, but protected the cells from attacks by the body’s immune system.
This eliminated the need for geneticmatching to patients, meaning that cells could be produced on an industrial scale and used in patients without the risk of immune rejection. A further advantage would be that the capsule of cells could be quickly removed and replaced if it stopped working.
Although insulin injections help to keep glucose levels broadly in check, they do not match the body’s fine tuning, and this lack of control can eventually lead to complications from blindness to the loss of limbs.
Richard Elliott, of Diabetes UK, said that the treatment could “transform” the lives of people with the condition, although it was likely to be years before the cell-based therapy could be used routinely. “It could mean they no longer need to use insulin, which would be a historic breakthrough,” he added.
The treatment could also help the one in ten sufferers of type 2 diabetes who rely on insulin injections. Type 2 diabetes, which is diet related, occurs when the insulin cells stop working properly or when the body stops responding normally to insulin.
The discovery of a new type of “good” fat made in the body could help to prevent and treat type 2 diabetes. The previously unidentified lipid molecules increase insulin sensitivity and blood sugar control.
Unlike omega-3 fatty acids found in oily fish, the good fat named fatty acid hydroxyl fatty acids, or FAHFAs, are molecules found in fat cells as well as other cells throughout the body.
The NHS estimates that in England there are 3.1 million people over 16 with diabetes but by 2030 the figure is expected to rise to 4.6 million, with nine out of ten sufferers having type 2 diabetes.
The new findings, made by a team of scientists from Beth Israel Deaconess Medical Center in Boston and the Salk Institute in California, were published online by the journal Cell.
Profile Professor Melton
The satisfaction for Doug Melton, right, is as much personal as it is professional. His son was found to have type 1 diabetes when he was six months old. Later, his daughter received the same diagnosis. The Harvard professor, who completed his PhD in molecular biology at Trinity College, Cambridge, told The New York Times: “Like any parent, I asked myself, ‘What can I do?’ The answer was to shift my research to an area that might help them. I wanted my children to know I was doing everything I could.”
He had to overcome scepticism and political hurdles. In 2001 he secured private funding when George W Bush cut research into new stem cell lines. In 2007 he appeared on Time magazine’s list of the 100 most influential people.
By James GallagherHealth editor, BBC News website
The hunt for a cure for type 1 diabetes has recently taken a “tremendous step forward”, scientists have said.
The disease is caused by the immune system destroying the cells that control blood sugar levels.
A team at Harvard University used stem cells to produce hundreds of millions of the cells in the laboratory.
Tests on mice showed the cells could treat the disease, which experts described as “potentially a major medical breakthrough”.
Beta cells in the pancreas pump out insulin to bring down blood sugar levels.
But the body’s own immune system can turn against the beta cells, destroying them and leaving people with a potentially fatal disease because they cannot regulate their blood sugar levels.
It is different to the far more common type 2 diabetes which is largely due to poor lifestyle.
Perfect cocktailThe team at Harvard was led by Prof Doug Melton who began the search for a cure when his son was diagnosed 23 years ago. He then had a daughter who also developed type 1.
He is attempting to replace the approximately 150 million missing beta cells, using stem cell technology.
He found the perfect cocktail of chemicals to transform embryonic stem cells into functioning beta cells.
Tests on mice with type 1 diabetes, published in the journal Cell, showed that the lab-made cells could produce insulin and control blood sugar levels for several months.
Dr Melton said: “It was gratifying to know that we could do something that we always thought was possible.
“We are now just one pre-clinical step away from the finish line.”
However, his children were not quite so impressed: “I think, like all kids, they always assumed that if I said I’d do this, I’d do it.”
If the beta cells were injected into a person they would still face an immune assault and ultimately would be destroyed.
More research is needed before this could become a cure.
‘Game-changer’Sarah Johnson, from the charity JDRF which funded the study, told the BBC: “This isn’t a cure, it is a great move along the path. It is a tremendous step forward.
“Replacing the cells that produce insulin as well as turning off the immune response that causes type 1 diabetes is the long-term goal.”
Prof Chris Mason, a stem cell scientist at University College London, said: “A scientific breakthrough is to make functional cells that cure a diabetic mouse, but a major medical breakthrough is to be able to manufacture at large enough scale the functional cells to treat all diabetics.
“This research is therefore a scientific and potentially a major medical breakthrough.
“If this scalable technology is proven to work in both the clinic and in the manufacturing facility, the impact on the treatment of diabetes will be a medical game-changer on a par with antibiotics and bacterial infections.”
Dr Gillian Morrison, from the University of Edinburgh, agreed that this “represents a real advance in the field”.
She said: “The next important challenge will be to find ways to maintain these cells inside the body so they are protected from the immune response and have long-term function.”
We were so thrilled to have hosted the first ever Sugarplum Children’s Picnic in Oxfordshire at the weekend – with around 40 children attending, half of whom had T1. Sharky & George kept them all entertained for 3 very hot hours, playing games including Tug of War, catapulting water bombs and lots of jumping on and under their multicoloured parachute – pictures below.
For tea they all sat on straw bales eating sandwiches, sugar free jelly, corn crisps, sausages and cup cakes (even children T1 are allowed a sweet cupcake once in a while!), whilst the grown ups all got to know each other and compared stories about living with a child (or in some cases, two children) with diabetes. Most amazing of all, was seeing the children compare pumps and do blood tests – something which would bring a tear to the eye of even the strongest oaf parents.
We look forward to welcoming many many more children and parents to the next picnic in 2015.
Apologies for my silence over the past month or so – i have been wanting to update the site on at least a weekly, if not daily, basis, but there just seems to be so much going on at the moment, most importantly, Aliena going onto to an insulin pump. I was so hoping to do a weekly update of how we were finding it, and i know its not too late, so will do a summary by the end of this week i hope. But for now, i will say it’s been AMAZING – life changing. Yes, ups and downs, but so so much easier than injecting her every time she eats.
And guess what makes it all so much easier – it’s PINK!!!!
Lots of other Sugarplum news to come……having to buy pump cases has inspired me to produce our won range of Sugarplum Children pen cases, insulin pouches and so on, so i will be in touch with everyone to get ideas and feedback, once I get the ball rolling. Initial meeting with production company is in 2 weeks, so watch this space.